Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Dow
Baxter
McKinsey
Merck

Last Updated: January 26, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for Quizartinib


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Quizartinib?

Quizartinib is an investigational drug.

There have been 32 clinical trials for Quizartinib. The most recent clinical trial was a Phase 3 trial, which was initiated on May 1st 2014.

The most common disease conditions in clinical trials are Leukemia, Leukemia, Myeloid, Acute, and Leukemia, Myeloid. The leading clinical trial sponsors are Daiichi Sankyo, Inc., National Cancer Institute (NCI), and Daiichi Sankyo Co., Ltd.

There are two hundred and eighty-six US patents protecting this investigational drug and two international patents.

Recent Clinical Trials for Quizartinib
TitleSponsorPhase
Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs Physician's Choice in Newly Diagnosed FLT3-ITD+ AMLDaiichi Sankyo Europe, GmbH, a Daiichi Sankyo CompanyPhase 3
Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs Physician's Choice in Newly Diagnosed FLT3-ITD+ AMLUniversity Hospital HeidelbergPhase 3
A Study to Determine the Absolute Oral Bioavailability of Quizartinib Using a Radiolabeled Microtracer in Healthy SubjectsDaiichi Sankyo, Inc.Phase 1

See all Quizartinib clinical trials

Clinical Trial Summary for Quizartinib

Top disease conditions for Quizartinib
Top clinical trial sponsors for Quizartinib

See all Quizartinib clinical trials

US Patents for Quizartinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Quizartinib ⤷  Sign up for a Free Trial Peptides and combination of peptides for use in immunotherapy against various tumors IMMATICS BIOTECHNOLOGY GMBH (Tuebingen, DE) ⤷  Sign up for a Free Trial
Quizartinib ⤷  Sign up for a Free Trial Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity The University of North Carolina at Chapel Hill (Chapel Hill, NC) ⤷  Sign up for a Free Trial
Quizartinib ⤷  Sign up for a Free Trial Peptides and combination of peptides for use in immunotherapy against various tumors IMMATICS BIOTECHNOLOGIES GMBH (Tuebingen, DE) ⤷  Sign up for a Free Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Quizartinib

Drugname Country Document Number Estimated Expiration Related US Patent
Quizartinib Argentina AR104113 2035-03-27 ⤷  Sign up for a Free Trial
Quizartinib Argentina AR112781 2035-03-27 ⤷  Sign up for a Free Trial
Quizartinib Australia AU2016239920 2035-03-27 ⤷  Sign up for a Free Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Dow
Baxter
McKinsey
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.